The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial.
M. Boccadoro
Consultant or Advisory Role - Celgene
Research Funding - Celgene
F. Cavallo
Honoraria - Celgene
A. Nagler
No relevant relationships to disclose
D. Ben Yehuda
No relevant relationships to disclose
P. Omedè
No relevant relationships to disclose
M. Cavalli
No relevant relationships to disclose
A. Levi
No relevant relationships to disclose
C. Crippa
No relevant relationships to disclose
A. Siniscalchi
No relevant relationships to disclose
P. Brasca
No relevant relationships to disclose
A. M. Carella
No relevant relationships to disclose
B. A. Zanetti
No relevant relationships to disclose
F. Patriarca
Honoraria - Celgene
S. Pezzati
No relevant relationships to disclose
V. Montefusco
No relevant relationships to disclose
A. Stanevsky
No relevant relationships to disclose
B. Lupo
No relevant relationships to disclose
T. Caravita
Consultant or Advisory Role - Celgene
Honoraria - Celgene
F. Di Raimondo
Honoraria - Celgene
A. P. Palumbo
Consultant or Advisory Role - Celgene
Honoraria - Celgene